Smoking rates among low-income patients are double those of the general population. Access to health care is an essential social determinant of health. Federally qualified health care centers (FQHC) are government-supported and community-based centers to increase access to health care for non-insured and underinsured patients. However, barriers to implementation impact adherence and sustainability of evidence-based smoking cessation within FQHC settings. To address this implementation barrier, our multi-disciplinary team proposes Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion) to establish the acceptability, feasibility, and capacity of an FQHC system to deliver an evidence-based and multi-level intervention to increase patient engagement with a state tobacco quitline. A mixed-method approach, rooted in an implementation science framework of RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance), will be used in this hybrid effectiveness-implementation design. We aim to evaluate the efficacy of a novel delivery system (patient portal) for increasing access to smoking cessation treatment. In preparation for a future randomized clinical trial of Mi QUIT CARE, we will conduct the following developmental research: (1) Examine the burden of tobacco among patient populations served by our partner FQHC, (2) Evaluate among FQHC patients and health care providers, knowledge, attitudes, barriers, and facilitators related to smoking cessation and our intervention components, (3) Evaluate the use of tailored communication strategies and patient navigation to increase patient portal uptake among patients, and (4) To test the acceptability, feasibility, and capacity of the partner FQHC to deliver Mi QUIT CARE. This study provides a model for developing and implementing smoking and other health promotion interventions for low-income patients delivered via patient health portals. If successful, the intervention has important implications for addressing a critical social determinant of cancer and other tobacco-related morbidities. U.S. National Institutes of Health Clinical Trials, NCT04827420, https://clinicaltrials.gov/ct2/show/NCT04827420.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674302 | PMC |
http://dx.doi.org/10.3389/fpubh.2021.762784 | DOI Listing |
Nicotine Tob Res
January 2025
Department of Population Health Sciences, University of Leicester, Leicester, UK.
Introduction: Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation may be associated with varenicline response, but to date no genome-wide association studies of varenicline response have been published.
Methods: In this study, we investigated the genetic contribution to varenicline effectiveness using two electronic health record-derived phenotypes.
Healthcare (Basel)
December 2024
Department of Health Administration, Gyeonggi University of Science and Technology, Gyeonggi 15073, Republic of Korea.
: Adolescent smoking can lead to various health problems including atherosclerosis and cardiovascular disease, making it more difficult to quit smoking during adulthood. This study aims to evaluate the effect of the ordinance by assessing adolescents' smoking cessation behaviors and environmental conditions, according to the "Ordinance for the Prevention of Child and Adolescent Smoking and Support for Smoking Cessation", which was enacted in 2019 in Gwangju City, South Korea, for the first time in the country. : The data for the analysis were obtained from the 2018 and 2021 Korea Youth Risk Behavior Survey.
View Article and Find Full Text PDFAnn LGBTQ Public Popul Health
December 2024
Department of Health Systems and Population Health, University of Washington, School of Public Health, Seattle, WA, USA.
The intersection between a minoritized sexual orientation identity and a U.S. military Veteran status places lesbian, gay, and bisexual (LGB) Veterans at increased risk for cigarette smoking.
View Article and Find Full Text PDFJTO Clin Res Rep
January 2025
Icahn School of Medicine at Mount Sinai, New York, New York.
Lung cancer remains a leading cause of cancer-related mortality globally and presents significant challenges in Egypt. In 2023, the first annual meeting of the Thoracic Oncology Multidisciplinary Faculty, organized by the Egyptian Cancer Research Network and the Egyptian Society of Respiratory Neoplasms, was held in Cairo, Egypt. The meeting aimed to address gaps in lung cancer management across Egypt and the broader Middle East and North Africa region.
View Article and Find Full Text PDFIntroduction: The impact of e-cigarette flavoring on e-cigarette uptake and switching to e-cigarettes among adults who smoke is critical to e-cigarette regulation in the United Sates. The purpose of this secondary analysis was to assess the impact of e-cigarette flavoring choice on e-cigarette uptake and changes in cigarette smoking in a large nationwide trial of e-cigarette provision in the United States.
Methods: A free four-week supply of e-cigarettes was provided with minimal instructions to use to adults who smoke (N = 427).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!